Vera Therapeutics' (VERA) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Vera Therapeutics' stock rating has been reaffirmed as "sell (D-)" by Weiss Ratings, amidst various analyst ratings including several "overweight" and "peer perform" evaluations.
• The company recently reported a quarterly loss of ($1.20) earnings per share, missing expectations by ($0.38), and analysts predict an annual loss of -2.89 earnings per share.
• Vera Therapeutics has seen significant institutional investment, with over 99% ownership by institutional investors, indicating strong confidence in the company's future.

Vera Therapeutics (NASDAQ:VERA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

VERA has been the topic of several other research reports. JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vera Therapeutics in a research note on Thursday, September 18th. Finally, Wolfe Research reiterated a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Vera Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $63.00.

Vera Therapeutics Stock Performance

VERA stock traded down $0.30 during midday trading on Wednesday, hitting $30.50. The company's stock had a trading volume of 1,248,477 shares, compared to its average volume of 1,495,381. The stock's 50-day moving average price is $23.84 and its 200 day moving average price is $23.12. The company has a quick ratio of 17.03, a current ratio of 17.03 and a debt-to-equity ratio of 0.16. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period last year, the firm earned ($0.62) earnings per share. As a group, research analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VERA. Quantbot Technologies LP bought a new position in shares of Vera Therapeutics in the second quarter worth $51,000. Quarry LP increased its stake in Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $60,000 after acquiring an additional 500 shares during the last quarter. AlphaQuest LLC increased its stake in Vera Therapeutics by 404.7% in the first quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock valued at $96,000 after acquiring an additional 3,213 shares during the last quarter. Virtus Investment Advisers LLC increased its stake in Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company's stock valued at $98,000 after acquiring an additional 539 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock valued at $99,000 after acquiring an additional 2,757 shares during the last quarter. Institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.